![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB)
Has Durable Efficacy and Differentiated Safety Compared to Efavirenz/Emtricitabine/Tenofovir DF (ATR)
in Treatment-naïve HIV-1 Infected Patients:
Week 96 Results
|
|
|
Reported by Jules Levin
Eleventh International Congress on Drug Therapy in HIV Infection
11-15 November, 2012, Glasgow, UK
A Zolopa1, JE Gallant2, C Cohen3, P Sax4, E DeJesus5, A Mills6, D Wohl7,
HC Liu8, MS Rhee8, J Szwarcberg8,
1Stanford University, Palo Alto, CA, US; 2Johns Hopkins School of Medicine, Baltimore, MD, US; 3Community Research Initiative of
New England, Boston, MA, US; 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 5Orlando Immunology
Center, Orlando, FL, US; 6Anthony Mills MD, Inc., Los Angeles, CA, US; 7University of North Carolina, Chapel Hill, NC, US;
8Gilead Sciences, Foster City, CA, US
![Glasgow1.gif](../images/111612/111612-9/Glasgow1.gif)
![Glasgow2.gif](../images/111612/111612-9/Glasgow2.gif)
![Glasgow3.gif](../images/111612/111612-9/Glasgow3.gif)
![Glasgow4.gif](../images/111612/111612-9/Glasgow4.gif)
![Glasgow5.gif](../images/111612/111612-9/Glasgow5.gif)
![Glasgow6.gif](../images/111612/111612-9/Glasgow6.gif)
![Glasgow7.gif](../images/111612/111612-9/Glasgow7.gif)
![Glasgow8.gif](../images/111612/111612-9/Glasgow8.gif)
![Glasgow9.gif](../images/111612/111612-9/Glasgow9.gif)
![Glasgow10.gif](../images/111612/111612-9/Glasgow10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|